Industry Research Reports

Part 1

Part 2

Part 3

Part 4

Part 5

Home > Reports > Medical Care > Omics Based Clinical Trials- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Omics Based Clinical Trials- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Industry: Medical Care

Published: 2025-02-07

Pages: 100 Pages

Report ld: 3670428

Request Sample

Pre-Order Enquiry

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description

The global market for Omics Based Clinical Trials was estimated to be worth US$ 2244 million in 2024 and is forecast to a readjusted size of US$ 3268 million by 2031 with a CAGR of 5.6% during the forecast period 2025-2031.

Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.

Omics Based Clinical Trials Market Size(US$)

M= millions and B=billions

Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.

This report aims to provide a comprehensive presentation of the global market for Omics Based Clinical Trials, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Omics Based Clinical Trials by region & country, by Type, and by Application.

The Omics Based Clinical Trials market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Omics Based Clinical Trials.

Market Segmentation

Report Metric
Details
Report Title
Omics Based Clinical Trials- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
Forecasted Market Size in 2031
US$ 3268 million
CAGR(2025-2031)
5.6%
Market Size Available for Years
2025-2031
Global Omics Based Clinical Trials Companies Covered
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer
Covance
Rebus Bio
Novo Nordisk
Global Omics Based Clinical Trials Market, by Region
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Omics Based Clinical Trials Market, Segment by Type
Interventional Studies
Observational Studies
Expanded Access Studies
Global Omics Based Clinical Trials Market, Segment by Application
Oncology
Cardiology
Respiratory Diseases
Skin Diseases
CNS Diseases
Immunology
Genetic Diseases
Other Indications
Forecast Units
Million USD
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Omics Based Clinical Trials company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Omics Based Clinical Trials in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Omics Based Clinical Trials in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

1 Market Overview
    1.1 Omics Based Clinical Trials Product Introduction
    1.2 Global Omics Based Clinical Trials Market Size Forecast (2020-2031)
    1.3 Omics Based Clinical Trials Market Trends & Drivers
        1.3.1 Omics Based Clinical Trials Industry Trends
        1.3.2 Omics Based Clinical Trials Market Drivers & Opportunity
        1.3.3 Omics Based Clinical Trials Market Challenges
        1.3.4 Omics Based Clinical Trials Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

2 Competitive Analysis by Company
    2.1 Global Omics Based Clinical Trials Players Revenue Ranking (2024)
    2.2 Global Omics Based Clinical Trials Revenue by Company (2020-2025)
    2.3 Key Companies Omics Based Clinical Trials Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Omics Based Clinical Trials Product Offered
    2.5 Key Companies Time to Begin Mass Production of Omics Based Clinical Trials
    2.6 Omics Based Clinical Trials Market Competitive Analysis
        2.6.1 Omics Based Clinical Trials Market Concentration Rate (2020-2025)
        2.6.2 Global 5 and 10 Largest Companies by Omics Based Clinical Trials Revenue in 2024
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omics Based Clinical Trials as of 2024)
    2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Interventional Studies
        3.1.2 Observational Studies
        3.1.3 Expanded Access Studies
    3.2 Global Omics Based Clinical Trials Sales Value by Type
        3.2.1 Global Omics Based Clinical Trials Sales Value by Type (2020 VS 2024 VS 2031)
        3.2.2 Global Omics Based Clinical Trials Sales Value, by Type (2020-2031)
        3.2.3 Global Omics Based Clinical Trials Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Oncology
        4.1.2 Cardiology
        4.1.3 Respiratory Diseases
        4.1.4 Skin Diseases
        4.1.5 CNS Diseases
        4.1.6 Immunology
        4.1.7 Genetic Diseases
        4.1.8 Other Indications
    4.2 Global Omics Based Clinical Trials Sales Value by Application
        4.2.1 Global Omics Based Clinical Trials Sales Value by Application (2020 VS 2024 VS 2031)
        4.2.2 Global Omics Based Clinical Trials Sales Value, by Application (2020-2031)
        4.2.3 Global Omics Based Clinical Trials Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region
    5.1 Global Omics Based Clinical Trials Sales Value by Region
        5.1.1 Global Omics Based Clinical Trials Sales Value by Region: 2020 VS 2024 VS 2031
        5.1.2 Global Omics Based Clinical Trials Sales Value by Region (2020-2025)
        5.1.3 Global Omics Based Clinical Trials Sales Value by Region (2026-2031)
        5.1.4 Global Omics Based Clinical Trials Sales Value by Region (%), (2020-2031)
    5.2 North America
        5.2.1 North America Omics Based Clinical Trials Sales Value, 2020-2031
        5.2.2 North America Omics Based Clinical Trials Sales Value by Country (%), 2024 VS 2031
    5.3 Europe
        5.3.1 Europe Omics Based Clinical Trials Sales Value, 2020-2031
        5.3.2 Europe Omics Based Clinical Trials Sales Value by Country (%), 2024 VS 2031
    5.4 Asia Pacific
        5.4.1 Asia Pacific Omics Based Clinical Trials Sales Value, 2020-2031
        5.4.2 Asia Pacific Omics Based Clinical Trials Sales Value by Region (%), 2024 VS 2031
    5.5 South America
        5.5.1 South America Omics Based Clinical Trials Sales Value, 2020-2031
        5.5.2 South America Omics Based Clinical Trials Sales Value by Country (%), 2024 VS 2031
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Omics Based Clinical Trials Sales Value, 2020-2031
        5.6.2 Middle East & Africa Omics Based Clinical Trials Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Omics Based Clinical Trials Sales Value Growth Trends, 2020 VS 2024 VS 2031
    6.2 Key Countries/Regions Omics Based Clinical Trials Sales Value, 2020-2031
    6.3 United States
        6.3.1 United States Omics Based Clinical Trials Sales Value, 2020-2031
        6.3.2 United States Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
        6.3.3 United States Omics Based Clinical Trials Sales Value by Application, 2024 VS 2031
    6.4 Europe
        6.4.1 Europe Omics Based Clinical Trials Sales Value, 2020-2031
        6.4.2 Europe Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
        6.4.3 Europe Omics Based Clinical Trials Sales Value by Application, 2024 VS 2031
    6.5 China
        6.5.1 China Omics Based Clinical Trials Sales Value, 2020-2031
        6.5.2 China Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
        6.5.3 China Omics Based Clinical Trials Sales Value by Application, 2024 VS 2031
    6.6 Japan
        6.6.1 Japan Omics Based Clinical Trials Sales Value, 2020-2031
        6.6.2 Japan Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
        6.6.3 Japan Omics Based Clinical Trials Sales Value by Application, 2024 VS 2031
    6.7 South Korea
        6.7.1 South Korea Omics Based Clinical Trials Sales Value, 2020-2031
        6.7.2 South Korea Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
        6.7.3 South Korea Omics Based Clinical Trials Sales Value by Application, 2024 VS 2031
    6.8 Southeast Asia
        6.8.1 Southeast Asia Omics Based Clinical Trials Sales Value, 2020-2031
        6.8.2 Southeast Asia Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
        6.8.3 Southeast Asia Omics Based Clinical Trials Sales Value by Application, 2024 VS 2031
    6.9 India
        6.9.1 India Omics Based Clinical Trials Sales Value, 2020-2031
        6.9.2 India Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
        6.9.3 India Omics Based Clinical Trials Sales Value by Application, 2024 VS 2031

7 Company Profiles
    7.1 Parexel International Corporation
        7.1.1 Parexel International Corporation Profile
        7.1.2 Parexel International Corporation Main Business
        7.1.3 Parexel International Corporation Omics Based Clinical Trials Products, Services and Solutions
        7.1.4 Parexel International Corporation Omics Based Clinical Trials Revenue (US$ Million) & (2020-2025)
        7.1.5 Parexel International Corporation Recent Developments
    7.2 Pharmaceutical Product Development (PPD)
        7.2.1 Pharmaceutical Product Development (PPD) Profile
        7.2.2 Pharmaceutical Product Development (PPD) Main Business
        7.2.3 Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Products, Services and Solutions
        7.2.4 Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Revenue (US$ Million) & (2020-2025)
        7.2.5 Pharmaceutical Product Development (PPD) Recent Developments
    7.3 Charles River Laboratory
        7.3.1 Charles River Laboratory Profile
        7.3.2 Charles River Laboratory Main Business
        7.3.3 Charles River Laboratory Omics Based Clinical Trials Products, Services and Solutions
        7.3.4 Charles River Laboratory Omics Based Clinical Trials Revenue (US$ Million) & (2020-2025)
        7.3.5 Charles River Laboratory Recent Developments
    7.4 ICON plc
        7.4.1 ICON plc Profile
        7.4.2 ICON plc Main Business
        7.4.3 ICON plc Omics Based Clinical Trials Products, Services and Solutions
        7.4.4 ICON plc Omics Based Clinical Trials Revenue (US$ Million) & (2020-2025)
        7.4.5 ICON plc Recent Developments
    7.5 SGS SA
        7.5.1 SGS SA Profile
        7.5.2 SGS SA Main Business
        7.5.3 SGS SA Omics Based Clinical Trials Products, Services and Solutions
        7.5.4 SGS SA Omics Based Clinical Trials Revenue (US$ Million) & (2020-2025)
        7.5.5 SGS SA Recent Developments
    7.6 Eli Lilly and Company
        7.6.1 Eli Lilly and Company Profile
        7.6.2 Eli Lilly and Company Main Business
        7.6.3 Eli Lilly and Company Omics Based Clinical Trials Products, Services and Solutions
        7.6.4 Eli Lilly and Company Omics Based Clinical Trials Revenue (US$ Million) & (2020-2025)
        7.6.5 Eli Lilly and Company Recent Developments
    7.7 Pfizer
        7.7.1 Pfizer Profile
        7.7.2 Pfizer Main Business
        7.7.3 Pfizer Omics Based Clinical Trials Products, Services and Solutions
        7.7.4 Pfizer Omics Based Clinical Trials Revenue (US$ Million) & (2020-2025)
        7.7.5 Pfizer Recent Developments
    7.8 Covance
        7.8.1 Covance Profile
        7.8.2 Covance Main Business
        7.8.3 Covance Omics Based Clinical Trials Products, Services and Solutions
        7.8.4 Covance Omics Based Clinical Trials Revenue (US$ Million) & (2020-2025)
        7.8.5 Covance Recent Developments
    7.9 Rebus Bio
        7.9.1 Rebus Bio Profile
        7.9.2 Rebus Bio Main Business
        7.9.3 Rebus Bio Omics Based Clinical Trials Products, Services and Solutions
        7.9.4 Rebus Bio Omics Based Clinical Trials Revenue (US$ Million) & (2020-2025)
        7.9.5 Rebus Bio Recent Developments
    7.10 Novo Nordisk
        7.10.1 Novo Nordisk Profile
        7.10.2 Novo Nordisk Main Business
        7.10.3 Novo Nordisk Omics Based Clinical Trials Products, Services and Solutions
        7.10.4 Novo Nordisk Omics Based Clinical Trials Revenue (US$ Million) & (2020-2025)
        7.10.5 Novo Nordisk Recent Developments

8 Industry Chain Analysis
    8.1 Omics Based Clinical Trials Industrial Chain
    8.2 Omics Based Clinical Trials Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Omics Based Clinical Trials Sales Model
        8.5.2 Sales Channel
        8.5.3 Omics Based Clinical Trials Distributors

9 Research Findings and Conclusion

10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
            10.1.1.1 Research Programs/Design
            10.1.1.2 Market Size Estimation
            10.1.1.3 Market Breakdown and Data Triangulation
        10.1.2 Data Source
            10.1.2.1 Secondary Sources
            10.1.2.2 Primary Sources
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Omics Based Clinical Trials Market Trends
 Table 2. Omics Based Clinical Trials Market Drivers & Opportunity
 Table 3. Omics Based Clinical Trials Market Challenges
 Table 4. Omics Based Clinical Trials Market Restraints
 Table 5. Global Omics Based Clinical Trials Revenue by Company (2020-2025) & (US$ Million)
 Table 6. Global Omics Based Clinical Trials Revenue Market Share by Company (2020-2025)
 Table 7. Key Companies Omics Based Clinical Trials Manufacturing Base Distribution and Headquarters
 Table 8. Key Companies Omics Based Clinical Trials Product Type
 Table 9. Key Companies Time to Begin Mass Production of Omics Based Clinical Trials
 Table 10. Global Omics Based Clinical Trials Companies Market Concentration Ratio (CR5 and HHI)
 Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omics Based Clinical Trials as of 2024)
 Table 12. Mergers & Acquisitions, Expansion Plans
 Table 13. Global Omics Based Clinical Trials Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
 Table 14. Global Omics Based Clinical Trials Sales Value by Type (2020-2025) & (US$ Million)
 Table 15. Global Omics Based Clinical Trials Sales Value by Type (2026-2031) & (US$ Million)
 Table 16. Global Omics Based Clinical Trials Sales Market Share in Value by Type (2020-2025)
 Table 17. Global Omics Based Clinical Trials Sales Market Share in Value by Type (2026-2031)
 Table 18. Global Omics Based Clinical Trials Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
 Table 19. Global Omics Based Clinical Trials Sales Value by Application (2020-2025) & (US$ Million)
 Table 20. Global Omics Based Clinical Trials Sales Value by Application (2026-2031) & (US$ Million)
 Table 21. Global Omics Based Clinical Trials Sales Market Share in Value by Application (2020-2025)
 Table 22. Global Omics Based Clinical Trials Sales Market Share in Value by Application (2026-2031)
 Table 23. Global Omics Based Clinical Trials Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
 Table 24. Global Omics Based Clinical Trials Sales Value by Region (2020-2025) & (US$ Million)
 Table 25. Global Omics Based Clinical Trials Sales Value by Region (2026-2031) & (US$ Million)
 Table 26. Global Omics Based Clinical Trials Sales Value by Region (2020-2025) & (%)
 Table 27. Global Omics Based Clinical Trials Sales Value by Region (2026-2031) & (%)
 Table 28. Key Countries/Regions Omics Based Clinical Trials Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
 Table 29. Key Countries/Regions Omics Based Clinical Trials Sales Value, (2020-2025) & (US$ Million)
 Table 30. Key Countries/Regions Omics Based Clinical Trials Sales Value, (2026-2031) & (US$ Million)
 Table 31. Parexel International Corporation Basic Information List
 Table 32. Parexel International Corporation Description and Business Overview
 Table 33. Parexel International Corporation Omics Based Clinical Trials Products, Services and Solutions
 Table 34. Revenue (US$ Million) in Omics Based Clinical Trials Business of Parexel International Corporation (2020-2025)
 Table 35. Parexel International Corporation Recent Developments
 Table 36. Pharmaceutical Product Development (PPD) Basic Information List
 Table 37. Pharmaceutical Product Development (PPD) Description and Business Overview
 Table 38. Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Products, Services and Solutions
 Table 39. Revenue (US$ Million) in Omics Based Clinical Trials Business of Pharmaceutical Product Development (PPD) (2020-2025)
 Table 40. Pharmaceutical Product Development (PPD) Recent Developments
 Table 41. Charles River Laboratory Basic Information List
 Table 42. Charles River Laboratory Description and Business Overview
 Table 43. Charles River Laboratory Omics Based Clinical Trials Products, Services and Solutions
 Table 44. Revenue (US$ Million) in Omics Based Clinical Trials Business of Charles River Laboratory (2020-2025)
 Table 45. Charles River Laboratory Recent Developments
 Table 46. ICON plc Basic Information List
 Table 47. ICON plc Description and Business Overview
 Table 48. ICON plc Omics Based Clinical Trials Products, Services and Solutions
 Table 49. Revenue (US$ Million) in Omics Based Clinical Trials Business of ICON plc (2020-2025)
 Table 50. ICON plc Recent Developments
 Table 51. SGS SA Basic Information List
 Table 52. SGS SA Description and Business Overview
 Table 53. SGS SA Omics Based Clinical Trials Products, Services and Solutions
 Table 54. Revenue (US$ Million) in Omics Based Clinical Trials Business of SGS SA (2020-2025)
 Table 55. SGS SA Recent Developments
 Table 56. Eli Lilly and Company Basic Information List
 Table 57. Eli Lilly and Company Description and Business Overview
 Table 58. Eli Lilly and Company Omics Based Clinical Trials Products, Services and Solutions
 Table 59. Revenue (US$ Million) in Omics Based Clinical Trials Business of Eli Lilly and Company (2020-2025)
 Table 60. Eli Lilly and Company Recent Developments
 Table 61. Pfizer Basic Information List
 Table 62. Pfizer Description and Business Overview
 Table 63. Pfizer Omics Based Clinical Trials Products, Services and Solutions
 Table 64. Revenue (US$ Million) in Omics Based Clinical Trials Business of Pfizer (2020-2025)
 Table 65. Pfizer Recent Developments
 Table 66. Covance Basic Information List
 Table 67. Covance Description and Business Overview
 Table 68. Covance Omics Based Clinical Trials Products, Services and Solutions
 Table 69. Revenue (US$ Million) in Omics Based Clinical Trials Business of Covance (2020-2025)
 Table 70. Covance Recent Developments
 Table 71. Rebus Bio Basic Information List
 Table 72. Rebus Bio Description and Business Overview
 Table 73. Rebus Bio Omics Based Clinical Trials Products, Services and Solutions
 Table 74. Revenue (US$ Million) in Omics Based Clinical Trials Business of Rebus Bio (2020-2025)
 Table 75. Rebus Bio Recent Developments
 Table 76. Novo Nordisk Basic Information List
 Table 77. Novo Nordisk Description and Business Overview
 Table 78. Novo Nordisk Omics Based Clinical Trials Products, Services and Solutions
 Table 79. Revenue (US$ Million) in Omics Based Clinical Trials Business of Novo Nordisk (2020-2025)
 Table 80. Novo Nordisk Recent Developments
 Table 81. Key Raw Materials Lists
 Table 82. Raw Materials Key Suppliers Lists
 Table 83. Omics Based Clinical Trials Downstream Customers
 Table 84. Omics Based Clinical Trials Distributors List
 Table 85. Research Programs/Design for This Report
 Table 86. Key Data Information from Secondary Sources
 Table 87. Key Data Information from Primary Sources
 Table 88. Business Unit and Senior & Team Lead Analysts


List of Figures
 Figure 1. Omics Based Clinical Trials Product Picture
 Figure 2. Global Omics Based Clinical Trials Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Global Omics Based Clinical Trials Sales Value (2020-2031) & (US$ Million)
 Figure 4. Omics Based Clinical Trials Report Years Considered
 Figure 5. Global Omics Based Clinical Trials Players Revenue Ranking (2024) & (US$ Million)
 Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Omics Based Clinical Trials Revenue in 2024
 Figure 7. Omics Based Clinical Trials Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 8. Interventional Studies Picture
 Figure 9. Observational Studies Picture
 Figure 10. Expanded Access Studies Picture
 Figure 11. Global Omics Based Clinical Trials Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 12. Global Omics Based Clinical Trials Sales Value Market Share by Type, 2024 & 2031
 Figure 13. Product Picture of Oncology
 Figure 14. Product Picture of Cardiology
 Figure 15. Product Picture of Respiratory Diseases
 Figure 16. Product Picture of Skin Diseases
 Figure 17. Product Picture of CNS Diseases
 Figure 18. Product Picture of Immunology
 Figure 19. Product Picture of Genetic Diseases
 Figure 20. Product Picture of Other Indications
 Figure 21. Global Omics Based Clinical Trials Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 22. Global Omics Based Clinical Trials Sales Value Market Share by Application, 2024 & 2031
 Figure 23. North America Omics Based Clinical Trials Sales Value (2020-2031) & (US$ Million)
 Figure 24. North America Omics Based Clinical Trials Sales Value by Country (%), 2024 VS 2031
 Figure 25. Europe Omics Based Clinical Trials Sales Value, (2020-2031) & (US$ Million)
 Figure 26. Europe Omics Based Clinical Trials Sales Value by Country (%), 2024 VS 2031
 Figure 27. Asia Pacific Omics Based Clinical Trials Sales Value, (2020-2031) & (US$ Million)
 Figure 28. Asia Pacific Omics Based Clinical Trials Sales Value by Region (%), 2024 VS 2031
 Figure 29. South America Omics Based Clinical Trials Sales Value, (2020-2031) & (US$ Million)
 Figure 30. South America Omics Based Clinical Trials Sales Value by Country (%), 2024 VS 2031
 Figure 31. Middle East & Africa Omics Based Clinical Trials Sales Value, (2020-2031) & (US$ Million)
 Figure 32. Middle East & Africa Omics Based Clinical Trials Sales Value by Country (%), 2024 VS 2031
 Figure 33. Key Countries/Regions Omics Based Clinical Trials Sales Value (%), (2020-2031)
 Figure 34. United States Omics Based Clinical Trials Sales Value, (2020-2031) & (US$ Million)
 Figure 35. United States Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
 Figure 36. United States Omics Based Clinical Trials Sales Value by Application (%), 2024 VS 2031
 Figure 37. Europe Omics Based Clinical Trials Sales Value, (2020-2031) & (US$ Million)
 Figure 38. Europe Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
 Figure 39. Europe Omics Based Clinical Trials Sales Value by Application (%), 2024 VS 2031
 Figure 40. China Omics Based Clinical Trials Sales Value, (2020-2031) & (US$ Million)
 Figure 41. China Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
 Figure 42. China Omics Based Clinical Trials Sales Value by Application (%), 2024 VS 2031
 Figure 43. Japan Omics Based Clinical Trials Sales Value, (2020-2031) & (US$ Million)
 Figure 44. Japan Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
 Figure 45. Japan Omics Based Clinical Trials Sales Value by Application (%), 2024 VS 2031
 Figure 46. South Korea Omics Based Clinical Trials Sales Value, (2020-2031) & (US$ Million)
 Figure 47. South Korea Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
 Figure 48. South Korea Omics Based Clinical Trials Sales Value by Application (%), 2024 VS 2031
 Figure 49. Southeast Asia Omics Based Clinical Trials Sales Value, (2020-2031) & (US$ Million)
 Figure 50. Southeast Asia Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
 Figure 51. Southeast Asia Omics Based Clinical Trials Sales Value by Application (%), 2024 VS 2031
 Figure 52. India Omics Based Clinical Trials Sales Value, (2020-2031) & (US$ Million)
 Figure 53. India Omics Based Clinical Trials Sales Value by Type (%), 2024 VS 2031
 Figure 54. India Omics Based Clinical Trials Sales Value by Application (%), 2024 VS 2031
 Figure 55. Omics Based Clinical Trials Industrial Chain
 Figure 56. Omics Based Clinical Trials Manufacturing Cost Structure
 Figure 57. Channels of Distribution (Direct Sales, and Distribution)
 Figure 58. Bottom-up and Top-down Approaches for This Report
 Figure 59. Data Triangulation
 Figure 60. Key Executives Interviewed

Description

The global market for Omics Based Clinical Trials was estimated to be worth US$ 2244 million in 2024 and is forecast to a readjusted size of US$ 3268 million by 2031 with a CAGR of 5.6% during the forecast period 2025-2031.

Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.

Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.

This report aims to provide a comprehensive presentation of the global market for Omics Based Clinical Trials, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Omics Based Clinical Trials by region & country, by Type, and by Application.

The Omics Based Clinical Trials market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Omics Based Clinical Trials.

Market Segmentation

Related Reports

Omics Based Clinical Trials - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
Published: 2024-01-11
Pages: 101
USD 3950.00
(Single User License)
Global Omics Based Clinical Trials Market Research Report 2024
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
Published: 2024-01-20
Pages: 81
USD 2900.00
(Single User License)
Global Omics Based Clinical Trials Market Research Report 2025
The global market for Omics Based Clinical Trials was valued at US$ 2244 million in the year 2024 and is projected to reach a revised size of US$ 3268 million by 2031, growing at a CAGR of 5.6% during the forecast period.
Published: 2025-02-07
Pages: 80
USD 2900.00
(Single User License)

Omics Based Clinical Trials - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
Published: 2024-01-11
Pages: 101
USD 3950.00 ()
Global Omics Based Clinical Trials Market Research Report 2024
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
Published: 2024-01-20
Pages: 81
USD 2900.00 ()
Global Omics Based Clinical Trials Market Research Report 2025
The global market for Omics Based Clinical Trials was valued at US$ 2244 million in the year 2024 and is projected to reach a revised size of US$ 3268 million by 2031, growing at a CAGR of 5.6% during the forecast period.
Published: 2025-02-07
Pages: 80
USD 2900.00 ()